Trial intelligence / Profile preview

Methotrexate vs placebo in steroid-dependent ulcerative colitis

2006-003607-40Phase 2Terminated

Sponsor: CHU de Besançon
Start: Aug 2008
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, double-blind trial in autoimmune colitis comparing Methotrexate with Placebo (2 arms). Primary endpoints: Treatment success at week 16 and Treatment success at week 24. Started Aug 2008; status: terminated.

Drugs

methotrexate

Conditions

autoimmune colitis

Beyond the preview

Go deeper on 2006-003607-40.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2006-003607-40.